 I Overview
Learn more
According to available data, the global adjuvant melanoma market is estimated to be a significant portion of the broader melanoma therapeutics market, with recent reports indicating a market size of around $7.4 billion in 2022, projected to grow to $18.62 billion by 2031, driven largely by the increasing adoption of immune checkpoint inhibitors like pembrolizumab and nivolumab as primary adjuvant therapies for high-risk melanoma patients.
Key points about the adjuvant melanoma market:
Dominant therapies:
Immune checkpoint inhibitors like pembrolizumab and nivolumab are currently the leading drugs in the adjuvant melanoma market due to their proven efficacy in improving recurrence-free survival in high-risk stage III melanoma patients.
Market growth drivers:
Increasing awareness about melanoma, advancements in early detection, and the development of more targeted and effective adjuvant therapies are driving market growth.
Clinical considerations:
Patient selection is crucial for adjuvant therapy, with stage III melanoma being the primary focus, and careful consideration of potential side effects associated with immunotherapy. |
I assume you know the market size for the Vaccine Ruck in this indication
which vaccine are you comparing it to ? |
yes its called standard of care ....
i assume the leach market is still taking a slice |
"which is why they consider $9 billion the true market size"* management estimate *This of course is the total global melanoma therapeutics markets, all stages and all treatment types. There will of course be a reasonable slice that Scancell can attempt to grab. |
Reform UK has won its first ever Welsh council seat in a landmark victory - with a higher vote share than Nigel Farage received in his constituency last year.
The populist party has booted out long-standing Labour from the seat of Trevethin and Penygarn (Torfaen) with an astounding 47 per cent of the vote. |
which is why they consider $9 billion the true market size |
I know it is adjuvant Inan. Should make Scancell even more attractive.
Abstract 9035: An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients |
High flyers eh .......
.
Think next leg down for the share price should be starting soon..... |
basically scancell in effect has a training center for high flyers
free at the point of need |
Room C209f Biodiscovery Institute
University Park
Nottingham
NG7 2RD
UK0115 8231854judith.ramage@nottingham.ac.ukBiography
Dr Judith Ramage is an Associate Professor within the Division of Cancer and Stem Cells, in the School of Medicine, at the university of Nottingham
She graduated from Glasgow University with a BSc in Immunology. She then went on to study Immunolgical T cell memory for her PhD in Professor Hill Gastons laboratory, initially at Birmingham University then at Cambridge University.
She moved to The University of Nottingham for her first postdoc within the group of Professor Lindy Durrant to study the molecular mechanisms of Cancer vaccine targeting.
In 2005 Dr Ramage designed and set up the only Msc in the Country focusing on tumour Immunology (MSc Cancer Immunology and Biotechnology). She is the course director of this course as well as the module convenor of the cancer vaccine module. Dr Ramage is also the teaching lead for the Division of Cancer and Stem cells.
Her work has specifically focused on the study of the avidity of T cell responses to self antigens as well examining the methods of altering both positive and negative co-stimulatory molecules on tumour targets and the abilty of T cells to transmigrate into the tumour.
Teaching Summary
Course Director Cancer Immunology and Biotechnology
Cancer Vaccines module Convenor
I initiated, designed and setup the only Cancer Immunology course in the UK. This course was established to met the rapid growth of cancer immunotherapy. The course is extremely popular with over 80 applicants per years. The course is intended to advance the students' knowledge of tumour immunology and to appreciate the contribution of immunological mechanisms to the development of anti-cancer therapies. We take on a maximum of 15 students per year. Students are trained to carry out critical evaluation of scientific papers and to develop the ability to report and interpret results. In addition they carry out a 6 month research project. The course attracts high calibre students and this is demonstrated through the grades achieved by the students on the course. Graduates have progressed to PhD study in laboratories around the world, in leading Immuno-Biotech companies, including Medimmune and the NIH laboratories headed by Steve Rosenberg. Indeed we have found this to be a good source of obtaining high calibre PhD students for the school.
Research Summary
Dr Ramage is a T cell tumour immunologist whose current areas of research are:
1. understanding the mechanisms of antigen specific T cell migration into tumours
2. generating monoclonal antibodies to tetraspanins expressed on T cells |
Pipeline ..........
as Lindy has Stated
There are probably 200 different types of cancer. Each of them has a very different signature. |
About us
Nottingham University Therapeutic Antibody Centre (NUTAC) is dedicated to producing novel therapeutic monoclonal antibodies (mAbs) for the treatment of cancer and infectious disease. It is a newly established unit, based on Professor Lindy Durrant’s track record for delivering innovative immunotherapeutic products to the clinic. Lindy Durrant is a Professor in Cancer Immunotherapy at the University and the CEO of Scancell Limited, the University spin-out company she established in 1997.
The mAb group at NUTAC have recently developed a technology to unlock the glycome to allow for the production of anti-glycan mAbs. This has the potential to identify numerous new targets typically missed in conventional screening strategies. Our ability to unlock the glycome presents a unique proposition for the diagnosis, treatment and prevention of disease. |
There are so many cancers and subtypes
if you think where scancells staff have come from and effectively trained by the best
who selected the best .... then carry that forward
The aim of this group is to study the alterations in cancer antigens and exploit these in the development of therapies. These antigens can be used to stimulate the immune system by generating vaccines against the target and also highly specific antibodies that can be home to tumours and stimulate multiple arms of the immune system to kill tumours.
--Professor Lindy Durrant, Chair of Cancer Immunotherapy |
To LSE Chat
lets not put the "cartwheels" before the horse ... |
scancell has an enormous pipeline at the flick of a switch |
just to put Genmab into perspective
Genmab has been granted the exclusive right to develop and commercialise the Scancell antibody in multiple novel potential therapeutic products for any and all potential disease areas, excluding cell therapy applications. Scancell will be eligible to receive upfront and potential development and commercialisation milestone payments, as well as royalties on products sold.
they don't have the expertise to operate in cell therapy
I think folks still have not quite understood how advanced scancell is |
Immune checkpoint therapy has revolutionized cancer treatment by blocking inhibitory pathways in T cells that limits the an effective anti-tumor immune response. Therapeutics targeting CTLA-4 and PD1/PDL1 have progressed to first line therapy in multiple tumor types with some patients exhibiting tumor regression or remission. However, the majority of patients do not benefit from checkpoint therapy emphasizing the need for alternative therapeutic options.
Lymphocyte Activation Gene 3 (LAG3) or CD223 is expressed on multiple cell types including CD4+ and CD8+ T cells, and Tregs, and is required for optimal T cell regulation and homeostasis. |
by the way that was the adjuvant setting Marcus ref BMS trial |
Fianlimab and cemiplimab-rwlc (Libtayo) showed persistent and significant clinical activity in patients with advanced melanoma, regardless of LAG-3 or PD-L1 expression, according to findings from a combined post hoc analysis of 3 independent cohorts from a phase 1 trial (NCT03005782) presented at the 2024 ESMO Congress.
Tumor responses assessed by blinded independent central review (BICR) in a combined cohort of 98 patients showed that at a median follow-up of 23 months (interquartile range, 15-31), the overall response rate (ORR) was 57% (95% CI 47%-67%), including a complete response (CR) rate of 25% and a partial response (PR) rate of 33%. The rates of stable disease (SD) and progressive disease (PD) were 17% and 15%, respectively. Seven percent of patients were not evaluable (NE), and 3% of patients did not reach CR or PD. The disease control rate (DCR) was 78% (95% CI, 68%-85%). The median time to response was 1.5 months, and the median time to CR was 4.1 months.
Notably, 70% of patients experienced some level of tumor reduction. The median duration of response (DOR) was not reached (NR; 95% CI, 23–not estimable [NE]). The median progression-free survival (PFS) was 24 months (95% CI, 12-NE); the 12- and 24-month PFS rates were 60% (95% CI, 49%-69%) and 49% (95% CI, 36%-62%), respectively. The median overall survival was NR (95% CI, 42-NE).
the key data
The median progression-free survival (PFS) was 24 months (95% CI, 12-NE); the 12- and 24-month PFS rates were 60% (95% CI, 49%-69%) and 49% (95% CI, 36%-62%), respectively.
(pfs scib1 80% currently)v 60% (dcr 84%)v 78%
however ... could ISCIB1 be added to improve on that as a synergistic approach
to make that combination more competitive than our current trial
this is the beauty of a good vaccine .... its synergistic
which is why i have always stated, that the value of Synergy and how it affects the competition using checkpoint, because with synergy they are not competition |
BMS need to talk. |
BMS
"We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,”
The RELATIVITY-098 trial in adjuvant melanoma failed to meet its primary endpoint of recurrence-free survival (RFS). This study compared nivolumab + relatlimab versus nivolumab monotherapy.
Melanoma remains a key indication for nivolumab, accounting for approximately 22% of its total revenue (Q4 2024 results). While the anti-PD-(L)1 space is highly competitive, cemiplimab has carved out a differentiated position in dermatology-oncology.
Notably, the cemiplimab + fianlimab combination is currently being evaluated in a Phase 3 trial for first-line metastatic melanoma against pembrolizumab, with pivotal data expected in H2 2025.
Moreover, updated data from ESMO 2024 highlighted promising mPFS outcomes for the cemiplimab + fianlimab combination. Additionally, a Phase 3 trial in adjuvant melanoma is actively enrolling patients (NCT05608291). |
Its astonishing that so many High Profile Ministers defending Deep Fake Reeves |
Yep...the market is a place of irony....and complete contradiction.
.
Fight the market at your peril.
.
Don't ridicule someone for mitigating their losses.
.
Everyone has a point they will sell at....EVERYONE.....
Even big investment funds ...they constantly assess.... |
'we have hints that it's good'
.
We've had more than hints along the way for years....but despite all the euphoria... the share price has crashed.
.
What's the point trying to assess the science when you're as good at using it profitably as inane ?
.
As he says....it's all beyond him ...he just needs to tell himself that !! |
'Beyond me '....
.
Most things in the market are 'beyond you' inane. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
